{
    "clinical_study": {
        "@rank": "3324", 
        "arm_group": [
            {
                "arm_group_label": "ND0612", 
                "arm_group_type": "Experimental", 
                "description": "Levodopa and carbidopa SC solution"
            }, 
            {
                "arm_group_label": "Oral levodopa and carbidopa", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral levodopa and carbidopa"
            }
        ], 
        "brief_summary": {
            "textblock": "An open label phase I/IIa study to evaluate the safety and tolerability of 6 different\n      doses/ infusion rates of subcutaneous (SC) ND0612 solution in PD patients; to determine if\n      continuous delivery of levodopa and carbidopa can provide reduced variability in plasma\n      concentration; to test and compare the PK profile of high and low concentrations of CD; to\n      assess preliminary efficacy."
        }, 
        "brief_title": "A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female PD patients of any race aged 30 to 80 years\n\n          2. PD diagnosis consistent with the UK PD Society Brain Bank criteria.\n\n          3. Stable doses of anti PD drugs for at least 30 days\n\n          4. PD patients with well-defined morning \"OFF\" and a good response to LD\n\n          5. MMSE score > 26\n\n          6. No clinically significant medical, psychiatric or laboratory abnormalities\n\n        Exclusion Criteria:\n\n          1. Atypical or secondary Parkinsonism.\n\n          2. Acute psychosis or hallucinations.\n\n          3. Subjects treated with neuroleptics\n\n          4. History of melanoma or significant skin disorders.\n\n          5. Prior neurosurgical procedure for PD.\n\n          6. Patients with a history of drug abuse or alcoholism\n\n          7. Clinically significant ECG abnormalities.\n\n          8. Renal or liver dysfunction\n\n          9. Subjects who have participated in another clinical study within 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "id_info": {
            "nct_id": "NCT02096601", 
            "org_study_id": "ND0612/004"
        }, 
        "intervention": [
            {
                "arm_group_label": "ND0612", 
                "description": "Levodopa and carbidopa SC solution", 
                "intervention_name": "Levodopa and carbidopa SC solution", 
                "intervention_type": "Drug", 
                "other_name": "ND0612"
            }, 
            {
                "arm_group_label": "Oral levodopa and carbidopa", 
                "description": "Oral levodopa and carbidopa", 
                "intervention_name": "Oral levodopa and carbidopa", 
                "intervention_type": "Drug", 
                "other_name": "Oral levodopa and carbidopa"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carbidopa", 
                "Levodopa"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "Motor fluctuations", 
            "levodopa pharmacokinetics", 
            "levodopa and carbidopa solution", 
            "continuous subcutaneous delivery"
        ], 
        "lastchanged_date": "March 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "West Bloomfield", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48034"
                    }, 
                    "name": "Henry Ford West Bloomfield Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel"
                    }, 
                    "name": "Hadassah Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel"
                    }, 
                    "name": "Tel Aviv Medical Center"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Israel"
            ]
        }, 
        "official_title": "A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD", 
        "overall_contact": {
            "email": "yael@neuroderm.com", 
            "last_name": "Yael Cohen, M.Pharm.", 
            "phone": "+97289462729"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Israel: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Adverse events frequency", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 weeks"
            }, 
            {
                "measure": "LD, CD and 3-OMD PK analysis from sample taken on Days 3, 4 and 5 will be used to determine the Fluctuation Index, its CV, AUC, Cmin, Cmax, and tmax.", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3 and 4"
            }, 
            {
                "measure": "Tolerability: Number of patients who discontinued due to adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096601"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "NeuroDerm Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Michael J. Fox Foundation for Parkinson's Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "NeuroDerm Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}